Erratum: Unique Features of Cortical Bone Stem Cells Associated with Repair of the Injured Heart (Circ Res. (2015) 117 (1024-1033) DOI: 10.1161/CIRCRESAHA.115.307362);Unique features of cortical bone stem cells associated with repair of the injured heart

Circulation Research

Volumn 117, Issue 12, 2015, Pages 1024-1033

  Mohsin, Sadia ^a   Troupes, Constantine D ^a   Starosta, Timothy ^a   Sharp, Thomas E ^a   Agra, Elorm J ^a   Smith, Shavonn ^a   Duran, Jason M ^a   Zalavadia, Neil ^a   Zhou, Yan ^b   Kubo, Hajime ^a   Berretta, Remus M ^a   Houser, Steven R ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Adult stem cells; Engraftment; Histamine; Paracrine factors; Proliferation; Survival

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE TRIPHOSPHATE; BETA3 INTEGRIN; BETA4 INTEGRIN; CALCIUM; CD82 ANTIGEN; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; DECAY ACCELERATING FACTOR; DEXAMETHASONE; ENDOGLIN; ENDOSIALIN; ENHANCED GREEN FLUORESCENT PROTEIN; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN LIKE 3; HISTAMINE; INTERLEUKIN 18; INTERLEUKIN 33; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; B LYMPHOCYTE; BLEACHING; BONE MARROW CELL; BRIGHT FIELD MICROSCOPY; CARDIAC DERIVED STEM CELL; CARDIAC STEM CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURFACE; CELL SURVIVAL; CORTICAL BONE; CORTICAL BONE STEM CELL; DENDRITIC CELL; DNA REPLICATION; FEMALE; GAP JUNCTION; HEART INJURY; HEART MUSCLE CELL; IMMUNOMODULATION; MACROPHAGE; MESENCHYMAL STEM CELL; MINIPIG; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CAT; CELL CULTURE; COCULTURE; HEART DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PATHOLOGY; PHYSIOLOGY; PIG; PROCEDURES; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; CATS; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; HEART DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, CARDIAC; SWINE; SWINE, MINIATURE;

EID: 84952628715     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/RES.0000000000000447     Document Type: Erratum

References (41)

1. Duran JM, Makarewich CA, Sharp TE, Starosta T, Zhu F, Hoffman NE, Chiba Y, Madesh M, Berretta RM, Kubo H, Houser SR. Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms. Circ Res. 2013; 113: 539-552. doi: 10.1161/CIRCRESAHA.113.301202.
2. Mohsin S, Khan M, Toko H, et al. Human cardiac progenitor cells engineered with pim-i kinase enhance myocardial repair. J Am Coll Cardiol. 2012; 60: 1278-1287. doi: 10.1016/j.jacc.2012.04.047.
3. Urbanek K, Torella D, Sheikh F, De Angelis A, Nurzynska D, Silvestri F, Beltrami CA, Bussani R, Beltrami AP, Quaini F, Bolli R, Leri A, Kajstura J, Anversa P. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci U S A. 2005; 102: 8692-8697. doi: 10.1073/pnas.0500169102.
4. Oskouei BN, Lamirault G, Joseph C, Treuer AV, Landa S, Da Silva J, Hatzistergos K, Dauer M, Balkan W, McNiece I, Hare JM. Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair. Stem Cells Transl Med. 2012; 1: 116-124. doi: 10.5966/sctm.2011-0015.
5. Karantalis V, DiFede DL, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The prospective randomized study of mesenchymal stem cell therapy in patients undergoing cardiac surgery (prometheus) trial. Circ Res. 2014; 114: 1302-1310. doi: 10.1161/CIRCRESAHA.114.303180.
6. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011; 378: 1847-1857. doi: 10.1016/ S0140-6736(11)61590-0.
7. Pätilä T, Lehtinen M, Vento A, et al. Autologous bone marrow mononuclear cell transplantation in ischemic heart failure: a prospective, controlled, randomized, double-blind study of cell transplantation combined with coronary bypass. J Heart Lung Transplant. 2014; 33: 567-574. doi: 10.1016/j. healun.2014.02.009.
8. Delewi R, van der Laan AM, Robbers LF, Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, Tio RA, Waltenberger J, Ten Berg JM, Doevendans PA, Gehlmann HR, van Rossum AC, Piek JJ, Zijlstra F; HEBE investigators. Long term outcome after mononuclear bone marrow or peripheral blood cells infusion after myocardial infarction. Heart. 2015; 101: 363-368. doi: 10.1136/heartjnl-2014-305892.
9. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012; 379: 895-904. doi: 10.1016/S0140-6736(12)60195-0.
10. Mohsin S, Siddiqi S, Collins B, Sussman MA. Empowering adult stem cells for myocardial regeneration. Circ Res. 2011; 109: 1415-1428. doi: 10.1161/CIRCRESAHA.111.243071.
11. Hong KU, Guo Y, Li QH, Cao P, Al-Maqtari T, Vajravelu BN, Du J, Book MJ, Zhu X, Nong Y, Bhatnagar A, Bolli R. c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. PLoS One. 2014; 9: e96725. doi: 10.1371/journal.pone.0096725.
12. Xie Y, Ibrahim A, Cheng K, Wu Z, Liang W, Malliaras K, Sun B, Liu W, Shen D, Cheol Cho H, Li T, Lu L, Lu G, Marbán E. Importance of cellcell contact in the therapeutic benefits of cardiosphere-derived cells. Stem Cells. 2014; 32: 2397-2406. doi: 10.1002/stem.1736.
13. Yang D, Wang W, Li L, Peng Y, Chen P, Huang H, Guo Y, Xia X, Wang Y, Wang H, Wang WE, Zeng C. The relative contribution of paracine effect versus direct differentiation on adipose-derived stem cell transplantation mediated cardiac repair. PLoS One. 2013; 8: e59020. doi: 10.1371/journal.pone.0059020.
14. Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH, Bae JW, Oh BH, Park YB, Kim HS. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol. 2008; 51: 933-943. doi: 10.1016/j. jacc.2007.11.040.
15. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol. 2011; 50: 280-289. doi: 10.1016/j. yjmcc.2010.08.005.
16. Tang JM, Wang JN, Zhang L, Zheng F, Yang JY, Kong X, Guo LY, Chen L, Huang YZ, Wan Y, Chen SY. VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res. 2011; 91: 402-411. doi: 10.1093/cvr/cvr053.
17. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, Morales AR, Da Silva J, Sussman MA, Heldman AW, Hare JM. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation. 2013; 127: 213-223. doi: 10.1161/CIRCULATIONAHA.112.131110.
18. Makarewich CA, Zhang H, Davis J, Correll RN, Trappanese DM, Hoffman NE, Troupes CD, Berretta RM, Kubo H, Madesh M, Chen X, Gao E, Molkentin JD, Houser SR. Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarction. Circ Res. 2014; 115: 567-580. doi: 10.1161/ CIRCRESAHA.115.303831.
19. Kubo H, Berretta RM, Jaleel N, Angert D, Houser SR. c-Kit+ bone marrow stem cells differentiate into functional cardiac myocytes. Clin Transl Sci. 2009; 2: 26-32. doi: 10.1111/j.1752-8062.2008.00089.x.
20. Liu SQ, Tefft BJ, Zhang D, Roberts D, Schuster DJ, Wu A. Cardioprotective mechanisms activated in response to myocardial ischemia. Mol Cell Biomech. 2011; 8: 319-338.
21. Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, Heldman AW, Hare JM. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res. 2014; 7: 769-780. doi: 10.1007/s12265-014-9594-0.
22. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, Salio M, Battaglia M, Latronico MV, Coletta M, Vivarelli E, Frati L, Cossu G, Giacomello A. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004; 95: 911-921. doi: 10.1161/01. RES.0000147315.71699.51.
23. Quijada P, Toko H, Fischer KM, Bailey B, Reilly P, Hunt KD, Gude NA, Avitabile D, Sussman MA. Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells. Circ Res. 2012; 111: 77-86. doi: 10.1161/CIRCRESAHA.112.265207.
24. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res. 2015; 116: 1413-1430. doi: 10.1161/ CIRCRESAHA.116.303614.
25. Quijada P, Sussman MA. Making it stick: chasing the optimal stem cells for cardiac regeneration. Expert Rev Cardiovasc Ther. 2014; 12: 1275-1288. doi: 10.1586/14779072.2014.972941.
26. Dakhlallah D, Zhang J, Yu L, Marsh CB, Angelos MG, Khan M. MicroRNA-133a engineered mesenchymal stem cells augment cardiac function and cell survival in the infarct heart. J Cardiovasc Pharmacol. 2015; 65: 241-251. doi: 10.1097/FJC.0000000000000183.
27. Dixit P, Katare R. Challenges in identifying the best source of stem cells for cardiac regeneration therapy. Stem Cell Res Ther. 2015; 6: 26. doi: 10.1186/s13287-015-0010-8.
28. Ho MS, Mei SH, Stewart DJ. The Immunomodulatory and Therapeutic Effects of Mesenchymal Stromal Cells for Acute Lung Injury and Sepsis. J Cell Physiol. 2015; 230: 2606-2617. doi: 10.1002/jcp.25028.
29. Ben Nasr M, Vergani A, Avruch J, et al. Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site. Acta Diabetol. 2015; 52: 917-927. doi: 10.1007/ s00592-015-0735-y.
30. Santarlasci V, Cosmi L, Maggi L, Liotta F, Annunziato F. IL-1 and T helper immune responses. Front Immunol. 2013; 4: 182. doi: 10.3389/ fimmu.2013.00182.
31. Delisle JS, Giroux M, Boucher G, Landry JR, Hardy MP, Lemieux S, Jones RG, Wilhelm BT, Perreault C. The TGF-β-Smad3 pathway inhibits CD28-dependent cell growth and proliferation of CD4 T cells. Genes Immun. 2013; 14: 115-126. doi: 10.1038/gene.2012.63.
32. Zhang N, Bevan MJ. TGF-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat Immunol. 2012; 13: 667-673. doi: 10.1038/ni.2319.
33. Wang DG, Zhang FX, Chen ML, Zhu HJ, Yang B, Cao KJ. Cx43 in mesenchymal stem cells promotes angiogenesis of the infarcted heart independent of gap junctions. Mol Med Rep. 2014; 9: 1095-1102. doi: 10.3892/ mmr.2014.1923.
34. Wang WE, Yang D, Li L, et al. Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adiposederived stem cells in infarcted myocardium. Circ Res. 2013; 113: 288-300. doi: 10.1161/CIRCRESAHA.113.300929.
35. Hawat G, Hélie P, Baroudi G. Single intravenous low-dose injections of connexin 43 mimetic peptides protect ischemic heart in vivo against myocardial infarction. J Mol Cell Cardiol. 2012; 53: 559-566. doi: 10.1016/j. yjmcc.2012.07.008.
36. Li J, Qi D, Cheng H, Hu X, Miller EJ, Wu X, Russell KS, Mikush N, Zhang J, Xiao L, Sherwin RS, Young LH. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. Proc Natl Acad Sci U S A. 2013; 110: 16133-16138. doi: 10.1073/pnas.1312775110.
37. Khan M, Nickoloff E, Abramova T, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res. 2015; 117: 52-64. doi: 10.1161/CIRCRESAHA.117.305990.
38. Ferreira-Martins J, Ogórek B, Cappetta D, et al. Cardiomyogenesis in the developing heart is regulated by c-kit-positive cardiac stem cells. Circ Res. 2012; 110: 701-715. doi: 10.1161/CIRCRESAHA.111.259507.
39. Yanagida E, Shoji S, Hirayama Y, Yoshikawa F, Otsu K, Uematsu H, Hiraoka M, Furuichi T, Kawano S. Functional expression of Ca2+ signaling pathways in mouse embryonic stem cells. Cell Calcium. 2004; 36: 135-146. doi: 10.1016/j.ceca.2004.01.022.
40. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med. 2013; 368: 1260. doi: 10.1056/NEJMc1300259.
41. Levick SP, Meléndez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res. 2011; 89: 12-19. doi: 10.1093/cvr/cvq272.